HR Execs on the Move

Slayback Pharma

www.slayback-pharma.com

 
Slayback Pharma LLC is a specialty pharmaceutical company focused on developing, manufacturing and sourcing of complex generic pharmaceutical products, with a specific emphasis on complex injectables and other non-solid oral products. Slayback has created a unique portfolio of complex generics by smart product selection and execution and connecting various dots through a network of contract R&D laboratories and manufacturing organizations, comprising smart and rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Pete Meyers
Chief Financial Officer Profile

Similar Companies

Molecular NeuroImaging

Molecular NeuroImaging is a New Haven, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Corium

Corium is a commercial-stage biopharmaceutical company that is leading the development and commercialization of central nervous system (CNS) healthcare therapies that provide clinicians with important treatment options for patients, their families, and their caregivers. Collaborating with some of the world`s largest pharmaceutical and consumer product companies, we have a track record and depth of experience in taking products from concept, through development, to manufacturing and final commercialization.

DestinationRX

DestinationRX is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

UDG Healthcare plc

UDG Healthcare plc, formerly United Drug, is a Dublin-based international company and partner to the healthcare industry, providing clinical, commercial, communication and packaging services.

Broadstep

CompassionWe embrace each persons’ journey, celebrating unique perspectives and situations free of judgment.TeamworkWe are one team. We celebrate each others’ successes and work together to overcome challenges.ExcellenceWe grow with each other, so we p...